Colchicine for the Reduction of Dependency and Vascular Events After an Acute Intracerebral Hemorrhage

Phase 3

Not yet recruiting

• Conditions: Colchicine; ICH - Intracerebral Hemorrhage; Stroke; Dependence
• Interventions: Drug: Colchicine 0.5 MG; Drug: Placebo

• Registration Number: NCT06587737
• Lead Sponsor: Population Health Research Institute

Brief Summary

Data indicate that patients with intracerebral hemorrhage (ICH) are at high risk for thromboembolic events and disability that is not being sufficiently mitigated by current treatment strategies. This is aggravated by the cessation of antithrombotic medications for significant periods after hemorrhage. These findings highlight the need for novel treatments that modify the high risk for major vascular events and functional outcomes in ICH survivors.

The objective of CoVasc-ICH 2 is to demonstrate that oral colchicine 0.5 mg daily is superior to placebo for improving the outcomes of ICH survivors with evidence or risk factors for atherosclerosis, when started within 72 hours from ICH onset.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2024-08-29
• Study First Submitted QC: 2024-09-04
• Study First Posted: 2024-09-19
• Status Verified: 2025-01
• Last Update Submitted: 2025-01-14
• Last Update Posted: 2025-01-15
• Study Start: 2025-06-30
• Primary Completion: 2028-06-30
• Study Completion: 2028-06-30

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 1125

Inclusion Criteria

Adult patients presenting with spontaneous intraparenchymal hemorrhage within 72 hours of symptom onset and qualifying for at least one of the following categories:

i. history of symptomatic coronary, peripheral and/or carotid artery disease (severe atherosclerotic vascular disease), or ii. visualized extracranial cervical/intracranial atherosclerotic disease causing any degree of stenosis/occlusion or presence of aortic arch plaque with maximum thickness ≥1 mm (moderate atherosclerotic vascular disease), or iii. two or more risk factors including: age 60 years or older, hypertension, dyslipidemia, diabetes mellitus, chronic kidney disease (eGFR: 15-50mL/min), history of ischemic stroke or current smoking (mild atherosclerotic vascular disease).

Exclusion Criteria

• secondary causes of ICH (such as trauma, macrovascular anomalies, neoplasms or bleeding diathesis)
• ICH volume more than 60ml in the last imaging scan prior to consent
• Glasgow Coma Scale (GCS) score less than 7 or being intubated at the time of consent
• inflammatory bowel disease or chronic diarrhea
• cirrhosis or severe hepatic dysfunction
• renal insufficiency (eGFR<15mL/min)
• concurrent or planned treatment with strong CYP3A4 inhibitors (atazanavir, clarithromycin, darunavir/ritonavir, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, tipranavir/ritonavir) or P-gp inhibitors (cyclosporine, ranolazine)
• pregnancy or breast-feeding
• known allergy or sensitivity to colchicine
• a strong indication for colchicine where assignment to placebo is deemed unacceptable
• estimated life expectancy less than 6 months at the time of enrollment, and
• inability to adhere to study procedures

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
colchicine 0.5mg OD	Colchicine 0.5 MG	-
placebo	Placebo	-

Primary Outcome Measures

Name	Time	Method
Efficacy: MACE and Dependency	through study completion, an average of 36 months	Treatment with colchicine will reduce the risk for major adverse cardiovascular events (MACE) and dependency
Safety: Symptomatic hematoma expansion, major gastrointestinal adverse reactions or infection rates	through study completion, an average of 36 months	There will be no clinically-important change in symptomatic hematoma expansion, major gastrointestinal adverse reactions or infection rates with oral colchicine 0.5mg OD compared with matching placebo